VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Consensus Target Price from Analysts

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has received an average rating of “Reduce” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $0.95.

VTGN has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen downgraded VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st.

VistaGen Therapeutics Stock Performance

VTGN opened at $0.69 on Wednesday. VistaGen Therapeutics has a one year low of $0.43 and a one year high of $5.14. The company has a market cap of $27.34 million, a P/E ratio of -0.38 and a beta of 0.31. The business’s 50-day simple moving average is $0.60 and its 200-day simple moving average is $0.98.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Monday, June 15th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 120.13%. The business had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.40 million. During the same quarter in the previous year, the company posted ($1.67) EPS. As a group, analysts predict that VistaGen Therapeutics will post -1.31 earnings per share for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

A number of large investors have recently made changes to their positions in VTGN. Bank of America Corp DE boosted its position in shares of VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after purchasing an additional 19,331 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of VistaGen Therapeutics in the 1st quarter valued at about $25,000. Marshall Wace LLP acquired a new stake in shares of VistaGen Therapeutics in the 2nd quarter valued at about $69,000. Jane Street Group LLC acquired a new stake in shares of VistaGen Therapeutics in the 2nd quarter valued at about $190,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of VistaGen Therapeutics in the 3rd quarter valued at about $112,000. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.